Jasper Therapeutics : Submission of Matters to a Vote of Security Holders - Form 8-K

Item 5.07. Submission of Matters to a Vote of Security Holders.

On December 15, 2023, Jasper Therapeutics, Inc. (the "Company") held a Special Meeting of Stockholders (the "Meeting"). At the Meeting, a total of 92,015,007 shares of the Company's voting common stock, or approximately 82% of the 111,575,261 shares of the Company's voting common stock, $0.0001 par value per share (the "Common Stock"), issued and outstanding as of November 15, 2023, the record date for the Meeting, were represented virtually or by proxy.

At the Meeting, the Company's stockholders considered two proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 20, 2023.

Set forth below is a brief description of each proposal voted upon at the Meeting and the voting results with respect to each proposal.

Proposal No. 1: To approve an amendment to the Company's Second Amended and Restated Certificate of Incorporation, as amended, to effect, in the sole discretion of the Board of Directors of the Company (the "Board") at any time on or before December 15, 2024, a reverse stock split of the Common Stock at a ratio to be determined by the Board within a range of 1-for-3 to 1-for-10 (or any number in between), without reducing the authorized number of shares of the Common Stock, and without further approval or authorization of its stockholders (the "Reverse Stock Split Proposal").

Votes For		Votes Against		Abstentions
91,108,798		873,917		32,292

Proposal No. 2: To approve an adjournment of the Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal.

Votes For		Votes Against		Abstentions
91,306,235		669,886		38,886

An adjournment of the Meeting was not necessary because there were sufficient votes in favor of the Reverse Stock Split Proposal.